MFDS — authorised 14 November 1983
- Marketing authorisation holder: NOVARTIS
- Status: likely_approved
🇰🇷 Sandimmune in South Korea
MFDS authorised Sandimmune on 14 November 1983
Marketing authorisation
Sandimmune in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Sandimmune approved in South Korea?
Yes. MFDS authorised it on 14 November 1983.
Who is the marketing authorisation holder for Sandimmune in South Korea?
NOVARTIS holds the South Korean marketing authorisation.